We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

63 hedge funds and large institutions have $408M invested in Ventyx Biosciences in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

15% more funds holding

Funds holding: 5563 (+8)

2.59% more ownership

Funds ownership: 65.51%68.1% (+2.6%)

9% less capital invested

Capital invested by funds: $448M → $408M (-$40.7M)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
1.06%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
13
Increased
26
Reduced
13
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VP
1
venBio Partners
California
$61.3M
TP
2
Third Point
New York
$52.7M
Citadel Advisors
3
Citadel Advisors
Florida
$47.6M -$308K -20,582 -0.5%
LGM
4
Logos Global Management
California
$28.3M -$3.01M -201,600 -8%
VC
5
Vivo Capital
California
$23.5M
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$23.3M -$3.42M -228,607 -11%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$19.3M +$11.3M +758,903 +93%
RI
8
RTW Investments
New York
$19M
EC
9
EcoR1 Capital
California
$15.9M
BlackRock
10
BlackRock
New York
$12.9M +$8.46M +565,853 +115%
FCM
11
Farallon Capital Management
California
$11.4M -$2.74M -183,632 -16%
QUSVM
12
Qiming U.S. Ventures Management
Washington
$11.1M
Vanguard Group
13
Vanguard Group
Pennsylvania
$11.1M +$6.43M +430,077 +90%
Wellington Management Group
14
Wellington Management Group
Massachusetts
$11M -$9.05M -605,350 -40%
CAM
15
Cormorant Asset Management
Massachusetts
$9.55M -$69.6K -4,660 -0.6%
DCM
16
Driehaus Capital Management
Illinois
$7.78M -$62.9K -4,211 -0.7%
American Century Companies
17
American Century Companies
Missouri
$5.17M +$447K +29,916 +8%
GPP
18
Great Point Partners
Connecticut
$4.76M +$790K +52,889 +16%
MCMC
19
Matrix Capital Management Company
New Hampshire
$4.1M
State Street
20
State Street
Massachusetts
$3.98M +$2.3M +154,141 +90%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$3.5M +$1.35M +90,551 +46%
Barclays
22
Barclays
United Kingdom
$3.41M -$159K -10,657 -4%
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$2.52M -$297K -19,900 -9%
Northern Trust
24
Northern Trust
Illinois
$2.04M +$1.2M +80,391 +93%
HighTower Advisors
25
HighTower Advisors
Illinois
$1.87M +$2.28M +152,581 New

VTYX Hedge Fund Activity: Q2 2022 in Review

63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2022, worth a combined $408M — down 9.1% from $448M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new VTYX positions and 4 closed out — a net gain of 9 holders — while 26 added to existing stakes and 13 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $11.3M. The largest seller was Wellington Management Group, cutting an estimated $9.05M.

  • 63 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2022, up from 55 in Q1 2022.
  • Funds reported $408M of Ventyx Biosciences stock for Q2 2022, down 9.1% quarter-over-quarter.
  • 13 funds opened new Ventyx Biosciences positions in Q2 2022 and 4 closed out, a net change of +9 holders.
  • The largest Ventyx Biosciences buyer in Q2 2022 was Fidelity Investments, an estimated $11.3M added.
  • The largest Ventyx Biosciences seller in Q2 2022 was Wellington Management Group, an estimated $9.05M sold.

Based on aggregated 13F filings for Q2 2022.